Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma : An international multicenter study
| Autor: | Balázs Gieszer, Agnes Bilecz, Anna Buder, Petr Jakubec, Zsolt Megyesfalvi, Walter Berger, Berta Mosleh, Walter Klepetko, Ferenc Rényi-Vámos, Luka Brcic, Martin Filipits, Michael Grusch, Izidor Kern, Konrad Hoetzenecker, Mir Alireza Hoda, Tanja Cufer, Vitezslav Kolek, Sven Seiwerth, Ondřej Fischer, Thomas Klikovits, Katharina Sinn, Katja Mohorcic, Balazs Dome, Marko Jakopović, Miroslav Samarzija, János Fillinger, Viktoria Laszlo, Ales Rozman, Balazs Hegedus, Jozef Skarda, R. Hritcu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
PD-L1
0301 basic medicine Oncology programmed death-ligand 1 medicine.medical_specialty medicine.medical_treatment Medizin 03 medical and health sciences 0302 clinical medicine programmed cell death 1 (PD-1) Internal medicine Medicine Malignant pleural mesothelioma (MPM) Stage (cooking) Lung cancer programmed death ligand 1 (PD-L1) udc:616-006 programirana celična smrt 1 business.industry Standard treatment Cancer Immunotherapy mezoteliom - anatomija in histologija - analiza medicine.disease mesothelioma - anatomy and histology - analysis ligand programirane celične smrti 1 Blockade 030104 developmental biology programmed cell death 1 030220 oncology & carcinogenesis 1malignant pleural mesothelioma Immunohistochemistry Original Article maligni plevralni mezoteliom prognosis business Cohort study |
| Zdroj: | Transl Lung Cancer Res Translational lung cancer research, vol. 10, pp. 1-14, 2021. |
| ISSN: | 2226-4477 |
| Popis: | Background: Programmed cell death 1/programmed death ligand 1 (PD-1/PD-L1) immune-checkpoint blockade is a promising new therapeutic strategy in cancer. However, expression patterns and prognostic significance of PD-L1 and PD-1 are still controversial in human malignant pleural mesothelioma (MPM). ----- Methods: Formalin-fixed paraffin-embedded (FFPE) tumor samples from 203 MPM patients receiving standard treatment without immunotherapy were collected from 5 European centers. PD-L1 and PD-1 expression of tumor cells (TCs) and tumor-infiltrating lymphocytes (TILs) were measured by immunohistochemistry and correlated with clinical parameters and long-term outcome. ------ Results: High (>10%) PD-L1 TC and PD-1 TILs expressions were found in 18 (8%) and 39 (24%) patients, respectively. PD-L1 was rarely expressed by TILs [≥1%, n=13 (8%); >10%, n=1]. No significant associations were found between the PD-L1 or PD-1 expression of TCs or TILs and clinicopathological parameters such as stage or histological subtype. Notably, patients with high (>10%) TC-specific PD-L1 expression exhibited significantly worse median overall survival (OS) (6.3 vs. 15.1 months of those with low TC PD-L1 expression; HR: 2.51, P10%) proved to be an independent negative prognostic factor for OS (HR: 2.486, P=0.005). There was no significant correlation between PD-L1 or PD-1 expression of TILs and OS. ----- Conclusions: In this multicenter cohort study, we demonstrate that high (>10%) PD-L1 expression of TCs independently predicts worse OS in MPM. Further studies are warranted to investigate the value of PD-L1/PD-1 expression as a marker for treatment response in MPM patients receiving immunotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|